Trial
NCT03893019
MB-CART20.1 Melanoma
Early Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Miltenyi Biomedicine GmbH
Collaborators
DLR German Aerospace Center
Condition
Melanoma (Skin)
Intervention
MB-CART20.1
Why stopped
The risk-benefit assessment was not as expected.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-05-16